PubMed Health⌕ Search

Biomedical subjects

M Berardet

Publications and source records attributed to M Berardet.

10 recordsLinked to original sources

Modulation of immune responses in mice by oral administration of niflumic acid.

The in vivo effects of non-steroidal anti-inflammatory drugs (NSAIDs) on the host immune system are still poorly understood. However, through inhibition of prostaglandin synthesis, NSAIDs may exhibit immunomodulating properties. The present work was aimed at evaluating the influence of niflumic acid on immune responses when administered orally for 7 consecutive days to 8-week-old inbred mice. Immunological tests were performed 24 h after the arrest of the treatment. At a dosage of 50 mg/kg/day, niflumic acid exerted noticeable immunostimulating effects, as shown by an increase in plaque-forming cell numbers after in vivo immunization with sheep red blood cells, an augmentation of spleen cell proliferation responses to stimulation with T- or B-cell mitogens and of T-cell cytotoxic response to allogenic cells. Phagocytosis-induced chemiluminescence of peritoneal macrophages was also enhanced whereas interleukin-1 production by these cells was depressed, but without concomitant modification in interleukin-2 production by T-cells. Increasing the niflumic acid dosage to 75 mg/kg resulted in the disappearance of the immunostimulatory effects on lymphocytes responses. Macrophage activities were affected similarly in mice receiving 50 mg/kg. These results demonstrate that niflumic acid is able to stimulate in vivo several immunological functions and, consequently, to maintain host immune defenses. Interestingly, it depressed interleukin-1 production, known to play a major role in the inflammatory process.

Administration, Oral↗

Aclacinomycin inhibits suppressor cells in vivo and in vitro.

After the intraperitoneal injection of aclacinomycin into mice, a variety of immune responses are increased. The responsible mechanism is the elimination of suppressor cells since aclacinomycin inhibits the expression of tolerance to SRBC in mice and diminishes the capacity of spleen cells from SRBC-tolerant mice to inhibit the response of normal animals upon adoptive transfer, either when injected to the donor tolerant mice before the cell transfer or when in vitro incubated with the tolerant cells for 1 hour: both treatments had eliminated suppressor cells from the tolerant spleen cell population.

Aclarubicin↗

Direct measure of the destruction of bone marrow cells, after their injection into variously pretreated syngeneic hosts.

125IUdR-labeled bone marrow cells have been injected into syngeneic mice and their destruction measured by counting daily the animals in toto in a gamma counter. In lethally irradiated recipients, the immediate cell loss was the greatest when the irradiation was delivered just prior to the cell transfer and the cellular multiplication in the spleen on day 7, the smallest. The slopes of the destruction between days 1 and 4 are closely comparable, whether the animals were irradiated 45, 21, or 4 hr before the cell transfer. The immediate cell loss was greater in untreated animals than in the cyclophosphamide-treated recipients and the slope of the destruction curve was higher in cyclophosphamide-treated than in untreated animals. The intensity of the restoration measured by the 125IUdR and 59Fe incorporation on day 6 is inversely correlated to the intensity of the early destruction.

Animals↗

Potentiated immune responses after administration of aclacinomycin.

After the intraperitoneal injection of aclacinomycin into mice, a variety of immune responses were increased. The total plaque-forming spleen cell response to SRBC was higher in treated animals than in controls, in spite of an apparent cytotoxic effects on B cells. The aclacinomycin-sensitive cell is apparently a long-lived cell, surviving adult thymectomy. Delayed-type hypersensitivity reactions were also augmented in treated animals, particularly those bearing tumors. In adjuvant-treated mice, the injection of aclacinomycin augments the immune response still further. Such observations should be taken into account in the establishment of clinical protocols associating immunotherapy and chemotherapy.

Aclarubicin↗